177 related articles for article (PubMed ID: 7694068)
1. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Balzarini J; Karlsson A; De Clercq E
Mol Pharmacol; 1993 Oct; 44(4):694-701. PubMed ID: 7694068
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues.
Balzarini J; Velazquez S; San-Felix A; Karlsson A; Perez-Perez MJ; Camarasa MJ; De Clercq E
Mol Pharmacol; 1993 Jan; 43(1):109-14. PubMed ID: 7678689
[TBL] [Abstract][Full Text] [Related]
3. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
Buckheit RW; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP
Virology; 1995 Jun; 210(1):186-93. PubMed ID: 7540784
[TBL] [Abstract][Full Text] [Related]
4. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
5. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives.
Baba M; De Clercq E; Tanaka H; Ubasawa M; Takashima H; Sekiya K; Nitta I; Umezu K; Walker RT; Mori S
Mol Pharmacol; 1991 Jun; 39(6):805-10. PubMed ID: 1711148
[TBL] [Abstract][Full Text] [Related]
6. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Debyser Z; Vandamme AM; Pauwels R; Baba M; Desmyter J; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11769-76. PubMed ID: 1376311
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
[TBL] [Abstract][Full Text] [Related]
10. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Vrang L; Walbers J; Zhang H; Oberg B; Vandamme AM; Camarasa MJ; De Clercq E
Virology; 1993 Jan; 192(1):246-53. PubMed ID: 7685964
[TBL] [Abstract][Full Text] [Related]
11. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
Balzarini J; Pelemans H; Aquaro S; Perno CF; Witvrouw M; Schols D; De Clercq E; Karlsson A
Mol Pharmacol; 1996 Aug; 50(2):394-401. PubMed ID: 8700148
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
Balzarini J; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; Bathurst IC; Barr PJ; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11831-8. PubMed ID: 1376314
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.
Balzarini J; Karlsson A; Vandamme AM; Pérez-Pérez MJ; Zhang H; Vrang L; Oberg B; Bäckbro K; Unge T; San-Félix A
Proc Natl Acad Sci U S A; 1993 Aug; 90(15):6952-6. PubMed ID: 7688467
[TBL] [Abstract][Full Text] [Related]
14. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; Tarpley WG; De Clercq E
J Virol; 1993 Sep; 67(9):5353-9. PubMed ID: 7688822
[TBL] [Abstract][Full Text] [Related]
15. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
16. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.
Balzarini J; Karlsson A; Meichsner C; Paessens A; Riess G; De Clercq E; Kleim JP
J Virol; 1994 Dec; 68(12):7986-92. PubMed ID: 7525984
[TBL] [Abstract][Full Text] [Related]
17. Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains.
Balzarini J; Baba M; De Clercq E
Antimicrob Agents Chemother; 1995 Apr; 39(4):998-1002. PubMed ID: 7540384
[TBL] [Abstract][Full Text] [Related]
18. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; De Clercq E
Virology; 1993 Oct; 196(2):576-85. PubMed ID: 7690501
[TBL] [Abstract][Full Text] [Related]
19. Novel [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2" -dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity.
de Castro S; Lobatón E; Pérez-Pérez MJ; San-Félix A; Cordeiro A; Andrei G; Snoeck R; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
J Med Chem; 2005 Feb; 48(4):1158-68. PubMed ID: 15715482
[TBL] [Abstract][Full Text] [Related]
20. Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase.
Debyser Z; Pauwels R; Baba M; Desmyter J; De Clercq E
Mol Pharmacol; 1992 May; 41(5):963-8. PubMed ID: 1375320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
